HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $140 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a 'Buy' rating on Neurocrine Biosciences (NASDAQ:NBIX) and maintained a price target of $140.
August 04, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Neurocrine Biosciences (NASDAQ:NBIX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $140.
The reiteration of a 'Buy' rating and maintenance of a high price target by a reputable analyst firm like HC Wainwright & Co. is a positive signal for Neurocrine Biosciences. This could potentially lead to an increase in investor confidence and a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100